Last updated: September 9, 2026
The intravenous immune globulin (IVIG) 10% liquid market is a concentrated, supply-constrained biologics market dominated by CSL Behring, Grifols, Takeda, Octapharma, and ADMA Biologics. Growth is driven by expanding diagnosis of primary and secondary immunodeficiency, chronic inflammatory neuropathies, and autoimmune disease. Revenue growth is constrained by donor-plasma availability, manufacturing lead times, hospital budget controls, and substitution toward subcutaneous immunoglobulin.
No single product defines the market. FDA-approved 10% liquid IVIG products include Privigen, Gamunex-C, Gammagard Liquid, Octagam 10%, Panzyga, Flebogamma DIF, and Asceniv. These products are licensed as biologics, so they are not interchangeable through a conventional generic pathway. The near-term competitive threat is commercial competition among originator and plasma-derived products, not FDA-approved biosimilar entry.
What is immune globulin intravenous (human), 10% liquid?
Immune globulin intravenous (human), 10% liquid is a sterile human plasma-derived immunoglobulin product containing approximately 100 mg/mL of IgG for intravenous infusion. It is manufactured from pooled human plasma and is used for replacement therapy and immunomodulation.
The principal FDA-recognized use categories include:
- Primary humoral immunodeficiency
- Chronic inflammatory demyelinating polyneuropathy
- Multifocal motor neuropathy for some products
- Immune thrombocytopenic purpura
- Kawasaki disease
- Chronic lymphocytic leukemia-associated hypogammaglobulinemia
- Dermatomyositis for selected products
- Other labeled or medically accepted off-label autoimmune uses
The products differ in plasma sourcing, purification, stabilizers, pH, osmolality, IgA content, infusion tolerability, concentration, and labeled indications. They are not clinically identical solely because each contains 10% IgG.
Which companies sell 10% liquid IVIG products?
The principal U.S. commercial products are:
| Product |
Company |
U.S. regulatory status |
Key commercial position |
| Privigen |
CSL Behring |
BLA biologic |
Major IVIG franchise with broad hospital and specialty distribution |
| Gamunex-C |
Grifols |
BLA biologic |
High-volume IVIG product with immune replacement and neurologic uses |
| Gammagard Liquid |
Takeda |
BLA biologic |
IVIG and subcutaneous immunoglobulin franchise |
| Octagam 10% |
Octapharma |
BLA biologic |
Broad IVIG product with hospital and specialty use |
| Panzyga |
Takeda |
BLA biologic |
Newer IVIG product competing on tolerability, supply, and indications |
| Flebogamma DIF |
Grifols |
BLA biologic |
Plasma-derived IVIG with international and U.S. presence |
| Asceniv |
ADMA Biologics |
BLA biologic |
Smaller U.S. supplier targeting immune-deficient patients |
FDA product labeling confirms that these products are plasma-derived immunoglobulin preparations with different licensed indications and administration requirements (U.S. Food and Drug Administration [FDA], 2024a, 2024b, 2024c).
How concentrated is the IVIG market?
The market is highly concentrated because entry requires:
- Access to large volumes of qualified plasma.
- Fractionation and purification capacity.
- Viral-clearance validation.
- Long-term pharmacovigilance systems.
- Regulatory approval for a complex biologic.
- Hospital and specialty-pharmacy distribution.
- Reliable reimbursement and supply allocation.
CSL Behring, Grifols, Takeda, and Octapharma control a substantial share of global plasma-derived immunoglobulin supply. ADMA is a smaller U.S.-focused participant. The leading manufacturers also sell albumin and coagulation products, allowing them to spread plasma procurement and manufacturing costs across multiple product categories.
How large is the immune globulin market?
Published market estimates vary because analysts use different definitions. Some measure all immunoglobulin products, while others separate IVIG, subcutaneous immunoglobulin, and plasma-derived therapies.
A defensible market view is:
| Market measure |
Current commercial interpretation |
| Global immunoglobulin market |
Multi-billion-dollar market with sustained mid-single-digit to high-single-digit growth |
| Global plasma-derived therapies |
Larger category including albumin and coagulation factors |
| U.S. IVIG market |
Largest national market and a key profit center for major suppliers |
| 10% liquid IVIG |
Core hospital and specialty-care segment, competing with other IVIG concentrations and SCIG |
| SCIG |
Fast-growing substitute in chronic maintenance treatment |
Company filings provide a clearer financial signal than syndicated market reports. CSL Behring identifies immunoglobulin as a major contributor to its plasma-derived therapies business. Grifols reports substantial revenue from immunoglobulin and other plasma-derived medicines. Takeda identifies immunoglobulin as a leading product category within its plasma-derived therapies portfolio (CSL, 2024; Grifols, 2024; Takeda, 2024).
Exact product-level revenue for Privigen, Gamunex-C, Gammagard Liquid, and Octagam 10% is generally not disclosed separately. Reported company segment figures include multiple plasma-derived products and should not be treated as individual IVIG sales.
What is driving IVIG market growth?
Expanding use in neurologic disease
Neurology is a major source of IVIG demand. Chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, myasthenia gravis, autoimmune encephalitis, and other immune-mediated neurologic disorders support high-dose and recurring treatment.
Neurologic indications can generate greater revenue per patient than replacement therapy because dosing is often weight-based and repeated at short intervals. They also expose manufacturers to utilization-management controls and payer scrutiny.
Growth in primary and secondary immunodeficiency
The number of diagnosed immunodeficient patients continues to increase as clinicians recognize antibody deficiencies associated with hematologic malignancies, transplantation, immunosuppressive therapy, and genetic disorders.
Replacement therapy tends to produce recurring demand. It is less dependent on acute hospital events than immunomodulatory treatment, but it remains sensitive to home-infusion capacity and the availability of subcutaneous alternatives.
Increased diagnosis and treatment of autoimmune disease
IVIG is used in selected autoimmune and inflammatory conditions, including immune thrombocytopenia, dermatomyositis, Kawasaki disease, and other disorders. Expanded clinical use increases demand but also raises payer management and evidence requirements.
Pricing and product-mix effects
The market has historically benefited from price increases, higher use in neurologic indications, and premium pricing for products with strong supply reliability. Price realization is limited by hospital contracting, group purchasing organizations, government reimbursement, and payer controls.
Products with lower infusion-related reactions, flexible administration, and broad indication coverage can defend premium pricing more effectively than products competing only on list price.
What is limiting IVIG supply and margins?
Plasma collection is the primary structural constraint. Manufacturers need large quantities of human plasma, and plasma cannot be produced synthetically at commercial scale.
Supply pressure is affected by:
- Donor recruitment and retention
- Collection-center capacity
- Donor compensation rules
- Labor availability
- Regulatory changes
- Manufacturing shutdowns
- Foreign plasma-export restrictions
- Transportation and cold-chain requirements
- Competing demand from other plasma-derived products
The COVID-19 period exposed the market’s sensitivity to collection disruptions. Plasma volumes recovered in major markets, but manufacturers continue to invest in collection centers, fractionation plants, purification technology, and inventory.
Margin expansion is possible when plasma collection grows faster than demand. Margins contract when manufacturers must pay more for donor compensation, accelerate capacity expansion, or allocate scarce product among high-value indications.
When does IVIG lose exclusivity?
There is no single exclusivity-loss date for immune globulin intravenous (human), 10% liquid because the category contains multiple BLAs and products.
FDA biologic exclusivity
Under the Biologics Price Competition and Innovation Act, a reference biologic receives 12 years of reference-product exclusivity from the date of first licensure, subject to statutory rules. Most leading 10% IVIG products were first approved many years ago, so their statutory exclusivity periods have expired.
That expiration does not create automatic generic substitution. A competitor must obtain its own BLA or pursue the biosimilar pathway. For plasma-derived IVIG, the practical barriers are substantial because the product depends on plasma collection, complex fractionation, viral clearance, and clinical comparability.
Patent exclusivity
Patent protection is product-specific and may cover:
- Purification processes
- Viral-inactivation methods
- Stabilizers
- Formulation pH and osmolality
- Container systems
- Administration methods
- Manufacturing controls
- Specific disease-treatment regimens
Many core IVIG products have older composition and manufacturing patents. Remaining patent value is more likely to reside in process improvements, formulation claims, delivery systems, or method-of-use claims than in the basic IgG composition.
What is the Orange Book status of 10% liquid IVIG?
The Orange Book is not the principal patent database for these products. IVIG products are approved under biologics license applications and are generally evaluated through the Purple Book and FDA biologics framework rather than the conventional drug-listing and Orange Book pathway.
The business implications are material:
- Conventional ANDA generic substitution does not apply.
- A competing IVIG product does not automatically substitute at the pharmacy.
- Interchangeability is not established merely by having the same 10% concentration.
- Hospital formularies and physician selection remain important.
- Biosimilar approval would require a separate FDA biologics application and would not necessarily create automatic substitution.
FDA labeling and the Purple Book are more relevant than Orange Book listings for regulatory status and reference-product analysis (FDA, 2024d).
Are there FDA-approved biosimilars for 10% IVIG?
As of the latest broadly available FDA biologics records, the commercial IVIG market does not have a mature biosimilar replacement cycle comparable to insulin, monoclonal antibodies, or erythropoietin.
The biosimilar risk is low in the near term for four reasons:
- IVIG is derived from pooled human plasma rather than a single engineered cell line.
- Product heterogeneity and donor variability complicate analytical comparability.
- Manufacturing process controls are central to product quality.
- Large plasma-collection networks are difficult to replicate.
A future entrant could pursue a biosimilar or a standalone BLA, but the likely market path is a new licensed plasma-derived product with differentiated indications, supply, or manufacturing rather than rapid pharmacy-level substitution.
What patent litigation affects IVIG products?
IVIG litigation risk is generally lower than in small-molecule markets because the primary competitive barriers are manufacturing, plasma supply, regulatory approval, and distribution.
Potential disputes can involve:
- Manufacturing-process patents
- Viral-inactivation technology
- Formulation stability
- Container and administration systems
- Trademark and trade dress
- Contract manufacturing
- Supply agreements
- Patent challenges connected to biosimilar or follow-on biologic development
Public IVIG competition has not produced a recurring, high-volume Paragraph IV litigation pattern comparable to small-molecule products. Paragraph IV certifications apply to ANDA products. Since IVIG products are biologics, a conventional ANDA Paragraph IV launch strategy is generally unavailable.
What formulations are protected by IVIG patents?
Formulation and process protection can cover:
- 10% IgG concentration
- Low-IgA formulations
- Stabilizer selection
- Proline or glycine systems
- pH range
- Osmolality
- Protein aggregation control
- Freeze-thaw stability
- Storage temperature
- Ready-to-use liquid presentation
- Single-use vial configuration
The commercial value of these claims depends on whether a competitor can design around them while maintaining product quality and FDA compliance. Process patents may be more difficult to avoid than formulation patents because they can cover specific purification or viral-clearance steps required for a competing product.
How does IVIG compare with subcutaneous immunoglobulin?
| Factor |
IVIG 10% liquid |
SCIG |
| Administration |
Intravenous infusion |
Subcutaneous infusion |
| Typical setting |
Hospital, infusion center, or home infusion |
Primarily home administration |
| Dosing pattern |
Often intermittent, high dose |
More frequent, smaller doses |
| Main strength |
High-dose immunomodulation and rapid IgG delivery |
Maintenance replacement therapy and patient convenience |
| Commercial risk |
Infusion-center capacity and acute-care utilization |
Cannibalization of chronic IVIG replacement demand |
| Manufacturer advantage |
Hospital contracts and broad indication coverage |
Home-care infrastructure and patient training |
SCIG is a direct competitive risk in chronic replacement therapy. It is less likely to replace high-dose IVIG used for acute or intensive immunomodulation. Manufacturers with both IVIG and SCIG products can shift patients within their own portfolios.
Which companies are challenging the market leaders?
Competition is concentrated among established plasma-product manufacturers:
- CSL Behring competes through Privigen, plasma collection scale, global manufacturing, and broad specialty distribution.
- Grifols competes through Gamunex-C, Flebogamma DIF, plasma-collection infrastructure, and a large immunoglobulin franchise.
- Takeda competes through Gammagard Liquid and Panzyga, supported by its plasma-derived therapies business.
- Octapharma competes through Octagam 10% and global plasma-product manufacturing.
- ADMA Biologics competes as a smaller U.S. supplier with Asceniv and a narrower commercial footprint.
The strongest competitive advantages are reliable supply, product availability, physician familiarity, contracting position, and reimbursement access. Product differentiation alone has limited value if a manufacturer cannot deliver consistently.
What licensing and manufacturing barriers affect IVIG?
Large-scale plasma fractionation creates high entry barriers. A credible entrant needs:
- A licensed collection network or long-term plasma supply contracts
- Fractionation capacity
- Validated pathogen-removal and viral-inactivation processes
- Batch-release testing
- Specialized biologics regulatory expertise
- Pharmacovigilance and traceability systems
- Distribution to hospitals and specialty pharmacies
- Sufficient working capital to fund inventory and capacity
Licensing transactions are more likely to involve regional commercialization, contract manufacturing, plasma supply, or portfolio acquisitions than a simple patent license. Plasma suppliers may also use strategic partnerships to secure access to fractionation capacity.
What is the financial trajectory for IVIG manufacturers?
The sector has a favorable long-term revenue profile but uneven short-term margins.
Revenue drivers
Revenue growth is supported by:
- More diagnosed immunodeficiency
- Greater neurologic use
- Expanded plasma collection
- Price and mix improvements
- Capacity additions
- Growth in specialty pharmacy and home infusion
- Broader access in emerging markets
Margin pressures
Profitability is constrained by:
- Plasma acquisition costs
- New collection-center investment
- Manufacturing expansion
- Quality-control costs
- Product shortages and allocation
- Hospital contracting
- Reimbursement restrictions
- Patient migration to SCIG
The largest manufacturers have stronger financial resilience because albumin, coagulation factors, and other plasma-derived products share procurement and production infrastructure. Smaller companies face higher unit costs and greater exposure to product-specific supply interruptions.
Revenue exposure by company
| Company |
IVIG financial exposure |
Main risk |
| CSL Behring |
High, but diversified across plasma-derived therapies |
Plasma costs and capacity execution |
| Grifols |
High, with major dependence on plasma-derived medicines |
Leverage, plasma procurement, operational execution |
| Takeda |
Material within a diversified pharmaceutical portfolio |
Portfolio allocation and plasma-product competition |
| Octapharma |
High within plasma-derived products |
Collection and manufacturing scale |
| ADMA Biologics |
High relative to company size |
Concentration, supply reliability, and reimbursement |
Product-level revenue is not separately reported consistently. Investors should use company segment revenue, volume growth, gross-margin trends, plasma collection growth, and capacity-expansion guidance rather than attempting to infer sales from prescription data alone.
What generic launch scenarios exist for 10% liquid IVIG?
Near-term scenario: continued originator competition
This is the most likely scenario. Products compete through supply reliability, contracting, clinical familiarity, and indications. Price erosion remains limited compared with small-molecule generics.
Medium-term scenario: new plasma-derived entrants
A new entrant could win share through a differentiated indication, lower infusion reaction profile, improved supply, or regional access. The launch would require substantial plasma and manufacturing investment.
Longer-term scenario: biosimilar or follow-on biologic entry
A biosimilar could create price pressure, but substitution would likely develop slowly. The clinical and manufacturing complexity of pooled plasma products makes a rapid, multi-entrant erosion cycle unlikely.
Substitution scenario: increased SCIG use
SCIG can reduce IVIG demand in chronic replacement therapy. It is less likely to displace high-dose IVIG in acute immune modulation and selected neurologic indications.
What is the geographic outlook for IVIG?
The United States remains the most commercially important market because of high utilization, specialty-care infrastructure, and relatively strong reimbursement. Europe has significant demand but faces national tendering, pricing controls, and plasma self-sufficiency policies.
Growth opportunities exist in:
- Asia-Pacific
- Latin America
- Middle Eastern specialty-care markets
- Countries expanding diagnosis of primary immunodeficiency
- Markets building home-infusion capabilities
Geographic expansion depends on regulatory approval, local reimbursement, plasma-import rules, and supply allocation. Plasma-derived products are strategically sensitive in many countries because governments treat immunoglobulin as an essential or shortage-prone medicine.
Key Takeaways
- Immune globulin intravenous (human), 10% liquid is a product category, not a single branded drug.
- Privigen, Gamunex-C, Gammagard Liquid, Octagam 10%, Panzyga, Flebogamma DIF, and Asceniv are major U.S. products.
- The market is concentrated and supply constrained because plasma collection and fractionation are difficult to replicate.
- Growth is supported by immunodeficiency, neurology, and autoimmune use.
- SCIG is the main substitution risk in chronic replacement therapy.
- Traditional ANDA generic competition and Paragraph IV litigation are not the primary market risks.
- Most statutory biologic exclusivity periods have expired, but manufacturing and supply barriers remain strong.
- No mature FDA-approved biosimilar cycle currently threatens rapid IVIG price erosion.
- Financial performance depends on plasma volumes, product mix, pricing, capacity expansion, and reimbursement.
- Company-level revenue figures are more reliable than product-level estimates because manufacturers rarely disclose sales for individual IVIG brands.
FAQs
Is immune globulin intravenous 10% liquid the same as Privigen?
No. Privigen is one branded 10% IVIG product. Gamunex-C, Gammagard Liquid, Octagam 10%, Panzyga, Flebogamma DIF, and Asceniv are separate biologic products with different labels, formulations, and manufacturers.
Can a pharmacy automatically substitute one 10% IVIG product for another?
Generally no. IVIG products are biologics, not conventional generic drugs. Substitution depends on the product’s regulatory status, payer policy, institutional formulary, and physician or pharmacist authority.
Does IVIG have patent protection after FDA biologic exclusivity expires?
Potentially. Patent protection may remain for manufacturing methods, formulations, stabilizers, delivery systems, or treatment methods even after statutory biologic exclusivity expires.
What is the largest long-term threat to IVIG revenue?
For chronic replacement therapy, SCIG adoption is the clearest substitution threat. For the overall market, plasma supply constraints and payer controls are more immediate commercial risks than generic price erosion.
Why is IVIG difficult for new companies to enter?
A new supplier needs qualified plasma, fractionation capacity, validated pathogen-reduction processes, extensive quality systems, regulatory approval, and specialized distribution. These requirements create higher barriers than those for most small-molecule drugs.
References
ADMA Biologics. (2024). Annual report and Asceniv prescribing information. https://www.admabiologics.com
CSL Limited. (2024). Annual report 2024. https://www.csl.com
Grifols, S.A. (2024). Annual report 2023. https://www.grifols.com
Takeda Pharmaceutical Company Limited. (2024). Annual report 2024. https://www.takeda.com
U.S. Food and Drug Administration. (2024a). Privigen prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2024b). Gamunex-C prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2024c). Gammagard Liquid, Octagam 10%, Panzyga, and Flebogamma DIF prescribing information. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (2024d). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
